SHMT2

Across TCGA pan-cancer cohorts, SHMT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SHMT2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SHMT2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SHMT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where SHMT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.298	0.670	.002	46	view →
CCRCC	DFS	Tertile	All	0.643	0.917	.011	34	view →
UCEC	OS	Quartile	III,IV	1.000	0.333	.042	4	view →
LUAD	OS	Quartile	All	0.408	0.903	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SHMT2–PDAC (OS)

Open the PDAC breakdown →